Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.
Department of Pathology, Aberdeen Royal Infirmary and Aberdeen University Medical School, Aberdeen, UK. Electronic address: clinicalguidelines@esmo.org.
K M
KM
Kerr
Institute for Pathology, University Hospital Basel, Basel, Switzerland.
L
L
Bubendorf
University of New Mexico Cancer Center, Albuquerque, USA.
M J
MJ
Edelman
Center of Predictive Molecular Medicine, Center of Excellence on Ageing, University-Foundation, Chieti, Italy.
A
A
Marchetti
Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin New Territories, Hong Kong, China.
T
T
Mok
Thoracic Oncology Unit, Department of Oncology, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Orbassano, Italy.
S
S
Novello
Trinity College, Dublin, Ireland; Queensland University of Technology, Brisbane, Australia.
K
K
O'Byrne
Clinic of Oncology, University Hospital Zürich, Zürich.
R
R
Stahel
Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
S
S
Peters
Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
E
E
Felip
D000077548:Anaplastic Lymphoma Kinase; D014408:Biomarkers, Tumor / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000235:genetics* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000473:pathology; D025202:Molecular Diagnostic Techniques / Q000379:methods; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics
D014408:Biomarkers, Tumor; D000077548:Anaplastic Lymphoma Kinase; C512478:EGFR protein, human; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases
ESMO; consensus; molecular testing; non-small-cell lung cancer; pathology; recommendations